Cargando…

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies

BACKGROUND: FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. METHODS: Patients (≥20 years old) self‐administered oral pemigatini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Yutaka, Kuboki, Yasutoshi, Furukawa, Masayuki, Mizuno, Nobumasa, Hara, Hiroki, Ioka, Tatsuya, Ueno, Makoto, Takahashi, Yasuo, Takahashi, Shunji, Takeuchi, Shinji, Lihou, Christine, Ji, Tao, Tian, Chenwei, Shimizu, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225205/ https://www.ncbi.nlm.nih.gov/pubmed/37000035 http://dx.doi.org/10.1002/cam4.5798

Ejemplares similares

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Pemigatinib for cholangiocarcinoma
Publicado: (2022)

Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
por: Puar, Akshan, et al.
Publicado: (2022)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
por: Alekseev, Oleg, et al.
Publicado: (2021)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1(N546K) Mutation
por: Capone, Stephen, et al.
Publicado: (2022)

Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
por: Yukutake, Masanobu, et al.
Publicado: (2022)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
por: Wadsley, Jonathan, et al.
Publicado: (2023)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
por: Gong, Xiaohua, et al.
Publicado: (2023)

Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer
por: Ueno, Makoto, et al.
Publicado: (2019)

A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma
por: Hempel, Louisa, et al.
Publicado: (2022)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
por: Gong, Xiaohua, et al.
Publicado: (2021)

A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2022)

WA102
por: Peters, K
Publicado: (1995)

Run 102
por: Schnell, Wolfgang
Publicado: (1971)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response
por: Bibeau, Kristen, et al.
Publicado: (2022)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
por: Pace, Angelica, et al.
Publicado: (2023)

China in the Fight Against the Ebola Crisis: Human Security Perspectives
por: Cui, Shunji
Publicado: (2018)

The decay of $^{102}$Cd
por: Hnatowich, D J, et al.
Publicado: (1970)

The decay of $^{102}Cd$
por: Hnatowich, D J, et al.
Publicado: (1970)

Demolition of Building 102
por: Balle, Christoph
Publicado: (2021)

102, Danysz Compound
Publicado: (1916)

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
por: Ueno, Makoto, et al.
Publicado: (2017)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

The decay of 8 min $^{102m}$Ag and 13 min $^{102g}$Ag
por: Hnatowich, D J, et al.
Publicado: (1971)

Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study
por: Ueno, Makoto, et al.
Publicado: (2021)

Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
por: Teruya, Natsuki, et al.
Publicado: (2023)

Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

102nd SPSC Meeting
Publicado: (2011)

NIMD - measurements on NM 102
por: Fiebig, A
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_dvtigf5tjh13fj2joeoaffai4d